Depression in adults: treatment and management (NICE guideline NG222)
This guideline cites 8 of the 62 landmark trials in our Psychiatry & psychotherapy register.
- Issued by
- NICE
- Year
- 2022
- Source
- National Institute for Health and Care Excellence. Depression in adults: treatment and management. NICE guideline [NG222]. Published 29 June 2022; last reviewed 30 January 2026.
NG222 replaced the 2009 depression guideline and reorganised treatment around a menu of equally weighted first-line options — psychological therapy, medication, or both — chosen with the patient rather than dictated by a stepped-care ladder, with severity split into 'less severe' and 'more severe' rather than graded by symptom count. It sets out sequencing for inadequate response, combination and augmentation in treatment-resistant depression, and relapse prevention including mindfulness-based cognitive therapy. The register trials the guideline rests on are grouped below by treatment modality.
Psychological therapy: CBT & behavioural activation3
- 2006Dimidjian BAPsychiatry · Depression · Behavioural activationIn 241 adults with MDD, behavioural activation achieved the same acute response in severe depression as paroxetine, cognitive therapy or pill placebo.Read →
- 2005DeRubeis-Hollon CorePsychiatry · Depression · CBT vs pharmaIn 240 outpatients with moderate-to-severe MDD, 16 weeks of cognitive therapy matched response and protected against relapse after taper compared with paroxetine or pill placebo.Read →
- 1989NIMH TDCRP CorePsychiatry · Depression · CBT vs pharmaIn 250 outpatients with major depression, 16 weeks of cognitive therapy or interpersonal psychotherapy achieved the same acute response as imipramine + clinical management or pill placebo + clinical management.Read →
Pharmacotherapy & sequenced next-step treatment1
- 2006STAR*D CorePsychiatry · Depression · Sequential strategiesIn 4,041 outpatients with MDD, a sequential 4-step pharmacological strategy with CBT as a switch or augmentation option achieved cumulative remission across steps relative to each prior step.Read →
Combination & augmentation in treatment-resistant depression1
- 2013CoBalTPsychiatry · Depression · Treatment-resistantIn 469 primary-care patients with antidepressant-resistant depression, 12–18 sessions of CBT added to usual care improved 6-month response and sustained benefit at 46 months compared with usual care alone.OR 3.26Read →
Relapse prevention: mindfulness-based cognitive therapy3
- 2015PREVENT 2015Psychiatry · Depression · Relapse preventionIn 424 adults in remission from recurrent depression, MBCT with antidepressant taper achieved the same 24-month relapse as maintenance antidepressant therapy.HR 0.8995% CI 0.67-1.18Read →
- 2004Ma & TeasdalePsychiatry · Depression · Relapse preventionIn 75 remitted MDD patients, MBCT + TAU again reduced 12-month relapse in the ≥3-episode subgroup compared with treatment as usual.36% vs 78%Read →
- 2000Teasdale MBCTPsychiatry · Depression · Relapse preventionIn 145 remitted MDD patients with ≥2 prior episodes, 8-session MBCT + treatment as usual reduced 60-week relapse in those with ≥3 episodes versus treatment as usual.37% vs 66%Read →
Published since the guideline1
- 2023Cuijpers 2023Psychiatry · Depression · Meta-analysisAcross 409 trials and 52,702 adults with depression, cognitive behavioural therapy produced moderate-to-large effects acutely and a durable edge long-term relative to waitlist, care-as-usual, pill placebo or antidepressants.Read →
Cited landmark trials not yet in the register5
Further landmark trials this guideline cites that are not (yet) covered in our register. Each links out to the study for further reading.
- 2018Cipriani antidepressant NMA
Network meta-analysis of 21 antidepressants in acute major depression.
- 2019PANDA
Sertraline vs placebo in primary care across the severity spectrum.
- 2021ANTLER
Maintaining vs discontinuing antidepressants in primary care.
- 2016COBRA
Behavioural activation non-inferior to CBT and cheaper to deliver.
- 2015REEACT
Computerised CBT added to usual GP care showed no benefit.
Every trial shown is one this guideline actually cites: each link was checked against the guideline's own reference list, and the few that a machine cannot match, a trial cited through a later follow-up, or a NICE guideline, which carries no DOI, were verified by hand against the full text. This is not the guideline's complete reference list, only the landmark trials it cites that our register holds.